Sarepta: Time to Buy?
September 05, 2017 at 12:31 PM EDT
Data from a small clinical trial for an experimental drug for Duchenne muscular dystrophy could provide a catalyst for this drug maker’s stock. Here’s why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|